Gallstones, as a common benign gallbladder disease worldwide, have a prevalence of approximately 6.1%. Although laparoscopic cholecystectomy (LC) is currently the mainstream treatment, its associated complications cannot be overlooked, including intra-abdominal bleeding, bile leakage, intra-abdominal infection, bile duct injury, and damage to surrounding organs. With a deeper understanding of the physiological functions of the gallbladder-such as bile concentration, lipid digestion, and neuroendocrine regulation-combined with advances in minimally invasive techniques, the concept of "gallbladder-preserving stone removal" has gradually emerged. This approach aims to remove gallstones while preserving the structure and function of the gallbladder. In recent years, choledochoscopic gallbladder-preserving surgery (CGPS) has gained consensus and been incorporated into relevant guidelines. However, gallbladder-preserving stone removal still faces key controversies, particularly the balance between "preserving organ function" and the risks of "high stone recurrence" and "technical complexity." Exploring more minimally invasive and standardized procedures, optimizing patient selection, and improving postoperative management strategies are critical directions for overcoming these challenges.
At present, the Department of Gastroenterology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology has successfully performed 18 cases of gallbladder-preserving stone extraction using EUS-guided gallbladder drainage (EUS-GBD). Utilizing a double-flanged metal stent (Hot AXIOS™ electrocautery-enhanced delivery system), the procedure is precisely guided by endoscopic ultrasound. With the electrocautery-enabled delivery system of the stent, a "one-step" technique is used to place one flange (also known as a "mushroom head") into the gallbladder and the other into the stomach or duodenum, thereby creating a temporary anastomosis. Two weeks after the procedure, once the fistulous tract has formed, a gastroscope is advanced into the gallbladder through the stent channel, and gallstones are removed using accessories such as a retrieval basket. After confirming complete stone clearance, the stent is removed, and the fistula is closed with titanium clips. As a natural orifice transluminal procedure, this approach offers several advantages, including minimal invasiveness, rapid postoperative recovery, avoidance of injury to surrounding organs such as the bile duct, and a low rate of postoperative complications. Moreover, it does not significantly affect subsequent surgical cholecystectomy if needed. However, the current overall sample size remains limited. Multicenter clinical studies with larger cohorts are still required to further evaluate the stone clearance rate and recovery of gallbladder contractile function, as well as to refine procedural techniques and postoperative management strategies, ultimately achieving standardization to facilitate broader clinical application. This study aims to evaluate the technical success rate and clinical efficacy of EUS-GBD combined with gallbladder stone extraction through a prospective clinical trial. In addition, long-term follow-up will be conducted to assess the incidence of short- and long-term postoperative complications, recovery of gallbladder function, and changes in patients' quality of life after minimally invasive, EUS-guided gallbladder-preserving stone removal. Ultimately, the study seeks to optimize the indications for this approach and to identify the best balance between "disease eradication" and "functional preservation."
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
EUS-GBD as a bridging procedure in combination of per-oral cholecystolithotomy
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The technical success rate
To evaluate the technical success rate of EUS-GBD combined with gallbladder stone extraction, defined as the successful placement of the LAMS and complete clearance of gallstones.
Time frame: From enrollment to the end of treatment at 1year
Gallbladder function
Gallbladder function will be compared before and after the procedure on the first month, the third month, the sixth month, and the twelfth month by ultrasound. It is measured by the percentage of gallbladder emptying (ejection fraction) reflecting the degree of gallbladder emptying and representing the percentage of initial volume evacuated by the contraction of the gallbladder. Gallbladder volume changes were determined using the Dodds formula: longitudinal diameter × transverse diameter × anteroposterior diameter × 0.52. The percentage of gallbladder emptying was calculated based on the volume differences as: \[(Fasting gallbladder volume - Residual gallbladder volume) / Fasting gallbladder volume)\] x 100.
Time frame: From enrollment to the end of treatment at 1year
The clinical success rate
Clinical success is defined as complete removal of gallstones.
Time frame: From enrollment to the end of treatment at 1year
Adverse events
Adverse events include the serious adverse events (SAEs) likely related to implanting procedures of LAMS, such as bleeding, peritonitis, perforation, stent misdeployment, and stent migration; and furthermore, the mild adverse events, including fever, pneumonia, elevated liver enzyme levels, and abdominal discomfort, respectively.
Time frame: From enrollment to the end of treatment at 1year
Procedure-related parameters
Procedure-related parameters include EUS-guided puncture sites either through stomach or duodenum, and the procedure time of the per-oral cholecystolithotomy is measured from the point of advancing endoscope into gallbladder via the fistula till withdrawal of the endoscope prior to closing the fistula.
Time frame: From enrollment to the end of treatment at 1year
Recurrence of gallstone
Recurrence of gallstone was defined as the presence of stone that was not detected at the first ultrosonography but was found during post-procedural follow-up ultrosonography.
Time frame: From enrollment to the end of treatment at 5 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.